Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01

Blood

Volumn 97, Issue 5, 2001, Pages 1211-1218

  Silverman, Lewis B ^a   Gelber, Richard D ^b   Dalton, Virginia Kimball ^b   Asselin, Barbara L ^b   Barr, Ronald D ^b   Clavell, Luis A ^b   Hurwitz, Craig A ^b   Moghrabi, Albert ^b   Samson, Yvan ^b   Schorin, Marshall A ^b   Arkin, Steven ^b   Declerck, Lieven ^b   Cohen, Harvey J ^b   Sallan, Stephen E ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ERWINIA ASPARAGINASE; ESCHERICHIA COLI ASPARAGINASE; FOLINIC ACID; METHOTREXATE; PREDNISONE; STEROID; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; TREATMENT OUTCOME;

EID: 0035283163     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1211     Document Type: Article

References (41)

1. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group
2. Improved outcome in childhood acute lymphobiastic leukaemia with reinforced early treatment and rotational combination chemotherapy
3. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X: Medical Research Council Working Party on Childhood Leukaemia
4. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
5. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01
6. Fouragent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
7. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
8. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: Cranial radiation requires an accomplice
9. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study
10. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial
11. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia
12. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia
13. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
14. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
15. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer institute Consortium
16. Nonparametric estimation from incomplete observations
17. Evaluation of survival data and two new rank order statistics arising in its consideration
18. Regression models and life-tables
19. Analysis of survival by tumor response
20. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia
21. High cure rate with a moderately intensive treatment regimen in non-high risk childhood acute lymphoblastic leukemia: Results of Protocol ALL VI from the Dutch Childhood Leukemia Study Group
22. Dexamethasone decreases central nervous system relapse and improves event-free survival in lower risk acute lymphoblastic leukemia
23. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
24. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone
25. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group
26. Prevention Of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group report
27. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study
28. Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNSdirected chemotherapy in four consecutive ALL-BFM trials
29. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation
30. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia: ISPACC: International Study Group on Psychosocial Aspects of Childhood Cancer
31. Biological and therapeutic aspects of infant leukemia
32. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review
33. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
34. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group
35. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
36. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
37. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
38. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
39. Incidence and clinical relevance of TEL/AML 1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials: Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group